Download PDF
Exp Clin Endocrinol Diabetes 2008; 116(1): 65-68
DOI: 10.1055/s-2007-985148
Short Communication

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Circulating FGF-21 Levels in Normal Subjects and in Newly Diagnose Patients with Type 2 Diabetes Mellitus

W.-W. Chen 1 , L. Li 2 , G.-Y. Yang 1 , K. Li 1 , X.-Y. Qi 1 , W. Zhu 1 , Y. Tang 3 , H. Liu 4 , G. Boden 5
  • 1Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
  • 2Department of Clinical Biochemistry and the Key Laboratory of Laboratory Medical Diagnostics in the Ministry of Education, Chongqing Medical University, Chongqing China
  • 3Oncology Research, Centocor, Inc., Malvern, Pennsylvania, USA
  • 4Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi, USA
  • 5The Division of Endocrinology/Diabetes/Metabolism and the Clinical Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania, USA
Further Information

Publication History

received 02.06.2007 first decision 12.06.2007

accepted 04.07.2007

Publication Date:
09 October 2007 (online)

Also available at
    Permissions and Reprints

Abstract

Fibroplast growth factor (FGF-21) is a recently discovered metabolic regulator. Its pathophysiologic role in humans remains unknown. In this study, we have investigated whether or not plasma FGF-21 level was different in patients with type 2 diabetes mellitus (T2DM) and non-diabetic controls. We also assessed associations between plasma FGF-21 body composition and several metabolic parameters. Fasting FGF-21 levels were significantly increased in patients with T2DM compared with controls (1.82±0.65 vs. 1.53±0.60 μg/L, P<0.05). In T2DM patients, fasting plasma FGF-21 correlate negatively with fasting blood glucose (r=-0.31, P<0.05). Multiple regression analysis showed that FBG, plasma insulin and HOMAIS were independent influencing plasma FGF-21 levels. The present work suggests a potential role for FGF-21 in the pathogenesis of insulin resistance and T2DM.

Key words

FGF-21 - insulin resistance - T2DM

References

  • 1 Sakaue H, Konishi M, Ogawa W, Asaki T, Mori T, Yamasaki M, Takata M, Ueno H, Kato S, Kasuga M, Itoh N. Requirement of fibroblast growth factor 10 in development of white adipose tissue.  Genes Dev. 2002;  16 908-912
    CrossrefPubMedGoogle Scholar
  • 2 Bhushan A, Itoh N, Kato S, Thiery JP, Czernichow P, Bellusci S, Scharfmann R. FGF10 is essential for maintaining the proliferative capacity of epithelial progenitor cells during early pancreatic organogenesis.  Development. 2001;  128 5109-5117
    PubMedGoogle Scholar
  • 3 Ohuchi H, Hori Y, Yamasaki M, Harada H, Sekine K, Kato S, Itoh N. FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development.  Biochem Biophys Res Commun. 2000;  277 643-649
    CrossrefPubMedGoogle Scholar
  • 4 Konishi M, Micami T, Yamasaki M, Miyake A, Itoh N. Fibroblast growth factor-16 is a growth factor for embryonic brown adipocytes.  J Biol Chem. 1999;  255 12119-12122
    PubMedGoogle Scholar
  • 5 Nishimura T, Utsonomiya Y, Hoshikawa M, Ohuchi H, Itoh N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain.  Biochim Biophys Acta. 1999;  1444 148-151
    CrossrefPubMedGoogle Scholar
  • 6 Xie MH, Holcomb I, Deuel B, Dowd P, Huang A, Vagts A, Foster J, Liang J, Brush J, Gu Q, Hillan K, Goddard A, Gurney AL. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4.  Cytokine. 1999;  11 729-735
    CrossrefPubMedGoogle Scholar
  • 7 Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity.  Endocrinology. 2002;  143 1741-1747
    CrossrefPubMedGoogle Scholar
  • 8 Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin deficient diabetes.  Endocrinology. 2004;  145 2594-2603
    CrossrefPubMedGoogle Scholar
  • 9 Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver.  Biochim Biophys Acta. 2000;  1492 203-206
    CrossrefPubMedGoogle Scholar
  • 10 Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator.  J Clin Invest. 2005;  115 1627-1635
    CrossrefPubMedGoogle Scholar
  • 11 Knebel B, Avci H, Bullmann C, Kotzka J, Müller-Wieland D. Reduced phosphorylation of transcription factor Elk-1 in cultured fibroblasts of a patient with premature aging syndrome and insulin resistance.  Exp Clin Endocrinol Diabetes. 2005;  113 94-101
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Wente W, Efanov AM, Brenner M, Kharitonenkov M, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J. Fibroblast growth factor-21 improves pancreatic ß-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.  Diabetes. 2006;  55 2470-2478
    CrossrefPubMedGoogle Scholar
  • 13 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation.  Diabetes Medicine. 1998;  15 539-553
    CrossrefPubMedGoogle Scholar
  • 14 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar

Correspondence

Dr. G.-Y. YangPhD 

Department of Endocrinology

The Second Affiliated Hospital

Chongqing Medical University

400010 Chongqing

China

Phone: +86/23/68 48 61 15

Fax: +86/23/68 48 61 15

Email: gangyiyang@yahoo.com.cn

      >